Eradication of glioblastoma by immuno-virotherapy with a retargeted oncolytic HSV in a preclinical model

Francesco Alessandrini, Laura Menotti, Elisa Avitabile, Irene Appolloni, Davide Ceresa, Daniela Marubbi, Gabriella Campadelli-Fiume, Paolo Malatesta

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Oncolytic herpes simplex viruses are proving to be effective in clinical trials against a number of cancers. Here, R-115, an oncolytic herpes simplex virus retargeted to human erbB-2, fully virulent in its target cells, and armed with murine interleukin-12 was evaluated in a murine model of glioblastoma. We show that a single R-115 injection in established tumors resulted, in about 30% of animals, in the complete eradication of the tumor, otherwise invariably lethal. The treatment also induced a significant improvement in the overall median survival time of mice and a resistance to recurrence from the same neoplasia. Such a high degree of protection was unprecedented; it was not observed before following treatments with the commonly used, mutated/attenuated oncolytic viruses. This is the first study providing the evidence of benefits offered by a fully virulent, retargeted, and armed herpes simplex virus in the treatment of glioblastoma and paves the way for clinical translation.

Original languageEnglish
JournalOncogene
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Oncolytic Viruses
Glioblastoma
Simplexvirus
Neoplasms
Interleukin-12
Therapeutics
Clinical Trials
Recurrence
Injections
Survival

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Eradication of glioblastoma by immuno-virotherapy with a retargeted oncolytic HSV in a preclinical model. / Alessandrini, Francesco; Menotti, Laura; Avitabile, Elisa; Appolloni, Irene; Ceresa, Davide; Marubbi, Daniela; Campadelli-Fiume, Gabriella; Malatesta, Paolo.

In: Oncogene, 01.01.2019.

Research output: Contribution to journalArticle

Alessandrini, F, Menotti, L, Avitabile, E, Appolloni, I, Ceresa, D, Marubbi, D, Campadelli-Fiume, G & Malatesta, P 2019, 'Eradication of glioblastoma by immuno-virotherapy with a retargeted oncolytic HSV in a preclinical model', Oncogene. https://doi.org/10.1038/s41388-019-0737-2
Alessandrini, Francesco ; Menotti, Laura ; Avitabile, Elisa ; Appolloni, Irene ; Ceresa, Davide ; Marubbi, Daniela ; Campadelli-Fiume, Gabriella ; Malatesta, Paolo. / Eradication of glioblastoma by immuno-virotherapy with a retargeted oncolytic HSV in a preclinical model. In: Oncogene. 2019.
@article{d0fda667f279425c8f26a506b0d14fa7,
title = "Eradication of glioblastoma by immuno-virotherapy with a retargeted oncolytic HSV in a preclinical model",
abstract = "Oncolytic herpes simplex viruses are proving to be effective in clinical trials against a number of cancers. Here, R-115, an oncolytic herpes simplex virus retargeted to human erbB-2, fully virulent in its target cells, and armed with murine interleukin-12 was evaluated in a murine model of glioblastoma. We show that a single R-115 injection in established tumors resulted, in about 30{\%} of animals, in the complete eradication of the tumor, otherwise invariably lethal. The treatment also induced a significant improvement in the overall median survival time of mice and a resistance to recurrence from the same neoplasia. Such a high degree of protection was unprecedented; it was not observed before following treatments with the commonly used, mutated/attenuated oncolytic viruses. This is the first study providing the evidence of benefits offered by a fully virulent, retargeted, and armed herpes simplex virus in the treatment of glioblastoma and paves the way for clinical translation.",
author = "Francesco Alessandrini and Laura Menotti and Elisa Avitabile and Irene Appolloni and Davide Ceresa and Daniela Marubbi and Gabriella Campadelli-Fiume and Paolo Malatesta",
year = "2019",
month = "1",
day = "1",
doi = "10.1038/s41388-019-0737-2",
language = "English",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Eradication of glioblastoma by immuno-virotherapy with a retargeted oncolytic HSV in a preclinical model

AU - Alessandrini, Francesco

AU - Menotti, Laura

AU - Avitabile, Elisa

AU - Appolloni, Irene

AU - Ceresa, Davide

AU - Marubbi, Daniela

AU - Campadelli-Fiume, Gabriella

AU - Malatesta, Paolo

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Oncolytic herpes simplex viruses are proving to be effective in clinical trials against a number of cancers. Here, R-115, an oncolytic herpes simplex virus retargeted to human erbB-2, fully virulent in its target cells, and armed with murine interleukin-12 was evaluated in a murine model of glioblastoma. We show that a single R-115 injection in established tumors resulted, in about 30% of animals, in the complete eradication of the tumor, otherwise invariably lethal. The treatment also induced a significant improvement in the overall median survival time of mice and a resistance to recurrence from the same neoplasia. Such a high degree of protection was unprecedented; it was not observed before following treatments with the commonly used, mutated/attenuated oncolytic viruses. This is the first study providing the evidence of benefits offered by a fully virulent, retargeted, and armed herpes simplex virus in the treatment of glioblastoma and paves the way for clinical translation.

AB - Oncolytic herpes simplex viruses are proving to be effective in clinical trials against a number of cancers. Here, R-115, an oncolytic herpes simplex virus retargeted to human erbB-2, fully virulent in its target cells, and armed with murine interleukin-12 was evaluated in a murine model of glioblastoma. We show that a single R-115 injection in established tumors resulted, in about 30% of animals, in the complete eradication of the tumor, otherwise invariably lethal. The treatment also induced a significant improvement in the overall median survival time of mice and a resistance to recurrence from the same neoplasia. Such a high degree of protection was unprecedented; it was not observed before following treatments with the commonly used, mutated/attenuated oncolytic viruses. This is the first study providing the evidence of benefits offered by a fully virulent, retargeted, and armed herpes simplex virus in the treatment of glioblastoma and paves the way for clinical translation.

UR - http://www.scopus.com/inward/record.url?scp=85061484274&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061484274&partnerID=8YFLogxK

U2 - 10.1038/s41388-019-0737-2

DO - 10.1038/s41388-019-0737-2

M3 - Article

AN - SCOPUS:85061484274

JO - Oncogene

JF - Oncogene

SN - 0950-9232

ER -